Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report) insider William Moschella sold 45,000 shares of Definitive Healthcare stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total value of $211,500.00. Following the completion of the transaction, the insider now owns 433,830 shares in the company, valued at $2,039,001. The trade was a 9.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Definitive Healthcare Trading Down 4.0 %
DH stock opened at $4.57 on Friday. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33. The firm has a market cap of $527.94 million, a P/E ratio of -1.47, a P/E/G ratio of 3.44 and a beta of 1.40. Definitive Healthcare Corp. has a 1-year low of $3.19 and a 1-year high of $10.62. The business's 50 day moving average is $4.38 and its 200-day moving average is $4.76.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the stock. Point72 DIFC Ltd grew its holdings in shares of Definitive Healthcare by 759.9% in the 3rd quarter. Point72 DIFC Ltd now owns 9,296 shares of the company's stock worth $42,000 after purchasing an additional 8,215 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Definitive Healthcare during the third quarter worth approximately $55,000. Bleakley Financial Group LLC bought a new position in shares of Definitive Healthcare in the third quarter valued at approximately $74,000. Glenmede Trust Co. NA boosted its holdings in shares of Definitive Healthcare by 41.1% in the 3rd quarter. Glenmede Trust Co. NA now owns 18,423 shares of the company's stock worth $82,000 after acquiring an additional 5,362 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Definitive Healthcare during the 3rd quarter valued at $84,000. 98.67% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
AI breakthrough about to upend industry
From Porter & Company | Ad
Everyone is talking about AI right now.
The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI.
But here’s the thing.
I urge you to watch it now.
A number of research firms have issued reports on DH. Needham & Company LLC reaffirmed a "hold" rating on shares of Definitive Healthcare in a report on Friday, November 8th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Definitive Healthcare from $7.00 to $5.00 and set a "hold" rating on the stock in a research report on Friday, August 9th. Finally, BTIG Research assumed coverage on shares of Definitive Healthcare in a research note on Tuesday, September 17th. They set a "buy" rating and a $7.00 target price for the company. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $5.81.
View Our Latest Analysis on DH
Definitive Healthcare Company Profile
(
Get Free Report)
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
